4A10 / Allterum - LARVOL DELTA

Advancing Hope for Children with Leukemia: Allterum Therapeutics Receives FDA Fast Track Designation for 4A10 in Acute Lymphoblastic Leukemia (PRWeb)

Fast track • Acute Lymphocytic Leukemia

Hope in Fight Against Pediatric Cancers: Allterum Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Appl. for 4A10 in Acute Lymphoblastic Leukemia (PRWeb) - "This clearance paves the way for the initiation of a Phase 1 first-in-human clinical trial in patients with Acute Lymphoblastic Leukemia (ALL)...The upcoming clinical trial will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of 4A10 in patients with relapsed or refractory ALL."

IND • New P1 trial • Acute Lymphocytic Leukemia

Allterum Therapeutics Awarded $1 Million SBIR Grant from NCI to Support Clinical Development of 4A10 in Childhood Leukemia (PRWeb) - "This grant provides critical non-dilutive funding to support Allterum's first-in-human clinical trial of 4A10 in patients with relapsed or refractory Acute Lymphoblastic Leukemia (ALL). The trial will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 4A10 in patients with T-Cell ALL (T-ALL), pre-B ALL, and lymphoblastic lymphoma."

Financing • New trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Lymphoblastic Lymphoma • T-cell Acute Lymphoblastic Lymphoma

In vitro and in vivo activity of the CD127 monoclonal antibody 4A10 in preclinical models of childhood acute lymphoblastic leukemia (AACR 2025) - "CD127 is an attractive target with a low risk of 'bystander toxicity' given limited CD127 expression in normal tissues as assessed by tissue cross-reactivity studies. In recent non-human primate studies, 4A10 therapy had a tolerable clinical profile with modest and reversible reduction in normal peripheral blood T-lymphocytes. Given the robust activity of 4A10 against multiple B-ALL subtypes, we will seek to extend our planned Phase 1/2A clinical trial assessing the safety and therapeutic efficacy of single agent 4A10 in adults and children with r/r ALL."

Preclinical • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia • ABL1 • CRLF2 • ETV6 • FCGR2A • FCGR2B • IL2RG • IL7 • IL7R • PBX1 • RUNX1 • STAT5 • TCF3 • TSLP

GBI Biomanufacturing and Allterum Therapeutics Announce Strategic Collaboration to Manufacture Therapeutic Antibody for Clinical Trials (Canada Newswire) - "GBI Biomanufacturing...and Allterum Therapeutics...are pleased to announce a manufacturing partnership to advance Allterum's lead candidate 4A10 into clinic. 4A10 is a monoclonal antibody (mAb) targeting CD127, a receptor expressed by a broad variety of cancers....With this collaboration, GBI will leverage their extensive expertise in manufacturing complex biologics to ensure the high-quality production of 4A10 for Phase 1/2a clinical trials. Allterum's initial trial will focus on patients who have acute lymphoblastic leukemia (ALL), with subsequent expansion to trials in patients with other CD127-expressing hematological malignancies, including lymphomas and acute myeloid leukemia."

Licensing / partnership • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology